Eyepoint Pharmaceuticals, Inc. $EYPT Shares Acquired by Deutsche Bank AG

Key Points

• Deutsche Bank AG increased its stake in Eyepoint Pharmaceuticals by 67.5%, acquiring an additional 144,060 shares, which brings its total holdings to 357,442 shares valued at approximately $1.94 million.
• Several institutional investors, including RA Capital Management and TCG Crossover Management, have significantly increased their positions in Eyepoint Pharmaceuticals, indicating strong institutional interest in the stock.
• Despite the positive sentiment, Eyepoint Pharmaceuticals reported a negative earnings per share of ($0.85) for the last quarter, missing analysts' expectations and reflecting ongoing challenges in revenue generation.

Deutsche Bank AG raised its holdings in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 67.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 357,442 shares of the company's stock after purchasing an additional 144,060 shares during the quarter. Deutsche Bank AG owned 0.52% of Eyepoint Pharmaceuticals worth $1,937,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE raised its position in shares of Eyepoint Pharmaceuticals by 28.8% in the fourth quarter. Bank of America Corp DE now owns 648,030 shares of the company's stock worth $4,828,000 after acquiring an additional 145,065 shares during the period. ProShare Advisors LLC raised its position in shares of Eyepoint Pharmaceuticals by 70.7% during the 4th quarter. ProShare Advisors LLC now owns 21,679 shares of the company's stock worth $162,000 after purchasing an additional 8,981 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Eyepoint Pharmaceuticals during the 4th quarter worth about $3,324,000. California State Teachers Retirement System raised its position in shares of Eyepoint Pharmaceuticals by 3.8% during the 4th quarter. California State Teachers Retirement System now owns 48,614 shares of the company's stock worth $362,000 after purchasing an additional 1,797 shares during the last quarter. Finally, MetLife Investment Management LLC raised its position in shares of Eyepoint Pharmaceuticals by 38.3% during the 4th quarter. MetLife Investment Management LLC now owns 40,502 shares of the company's stock worth $302,000 after purchasing an additional 11,217 shares during the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EYPT has been the subject of several research analyst reports. Mizuho reduced their price target on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, May 16th. HC Wainwright upped their price target on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Chardan Capital restated a "buy" rating and set a $27.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. Finally, Royal Bank Of Canada initiated coverage on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, June 17th. They set an "outperform" rating and a $28.00 price target for the company. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Eyepoint Pharmaceuticals has an average rating of "Buy" and a consensus price target of $25.38.

Eyepoint Pharmaceuticals Trading Down 1.7%

EYPT stock traded down $0.20 during mid-day trading on Wednesday, reaching $11.84. The company's stock had a trading volume of 496,026 shares, compared to its average volume of 700,943. The stock has a market cap of $816.13 million, a PE ratio of -4.42 and a beta of 1.73. Eyepoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $13.98. The company's 50 day moving average is $10.33 and its two-hundred day moving average is $7.78.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.18). The business had revenue of $5.33 million during the quarter, compared to analyst estimates of $6.82 million. Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. On average, analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.